Comparative Efficacy of a Biocompatible Citrate-Functionalized Magnetic Fluid Mediating Radiofrequency Hyperthermia and Magnetohyperthermia to Treat Ectopic Ehrlich-Solid-Tumor-Bearing Elderly MiceWanessa Pedroso Neves1,2,#, Cesar Romero Soares Sousa1,3,#, Ana Luisa Miranda-Vilela1*, Gisele Lorranna Silva Santos1, Paulo Eduardo N de Souza4, JoÃ£o Paulo FigueirÃ³ Longo1, and Zulmira Guerrero Marques Lacava1
- *Corresponding Author:
- Ana Luisa Miranda-Vilela
Department of Genetics and Morphology
Institute of Biological Sciences
University of BrasÃlia, Brasilia, Brazil
E-mail: [email protected]
Received date: March 21, 2017; Accepted date: April 04, 2017; Published date: April 10, 2017
Citation: Neves WP, Soares Sousa CR, Miranda-Vilela AL, Silva Santos GL, de Souza PEN, et al. (2017) Comparative Efficacy of a Biocompatible Citrate-Functionalized Magnetic Fluid Mediating Radiofrequency Hyperthermia and Magnetohyperthermia to Treat Ectopic Ehrlich-Solid-Tumor-Bearing Elderly Mice.J Cancer Sci Ther 9:393-392. doi: 10.4172/1948-5956.1000448
Copyright: © 2017 Neves WP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: We aimed to evaluate the efficacy of a biocompatible citrate-functionalized magnetic fluid (NPCit) sample in mediating hyperthermia, using two types of alternated (AC) magnetic field equipment operating in two different ways: a portable apparatus, generating an electromagnetic field in MHz range (radiofrequency range; radiofrequency hyperthermia-RFHT) developed by our research group (CMagMHG), and a commercial one working in kHz range (magnetohyperthermia-MHT) (Magnetherm, NanoTherics Ltd, Newcastle, United Kingdom), to treat ectopic Ehrlich-solid-tumor-bearing elderly mice.
Methods: Females intraperitoneally anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/Kg) were subcutaneously inoculated with Ehrlich ascitic tumor cell suspension (1.03 × 106 viable cells) in the upper head region for solid form implantation. After 48 hours, mice received one of four treatments: (a) filtered water and no tumor implantation (negative control); (b) tumor inoculation and no treatment (tumor control); (c) intratumoral injection of NPCit (40 µL) containing 18 × 1018 particles/mL and 13 minutes’ exposure to CMagMHG, operating at 1MHz, 40 Oe field amplitude; (d) intratumoral injection of NPCit and 13 minutes’ exposure to Magnetherm, assembled with 17-turn coil, capacitive box B22, operating under 330 kHz, 4.9 A, 25 V and maximum field strength 170 Oe. Treatments occurred once daily for three consecutive days. Tumor histopathology and semi-quantitative analysis of necrosis area served to assess tumor aggressiveness and regression. Possible acute side effects were assessed by animals’ body and spleen weight and hemogram.
Results: NPcit showed adequate biocompatibility and was effective in mediating RFHT and MHT, which promoted significant increases in necrosis area using both equipment types.
Conclusion: Our findings evidence the potential use of NPcit mediating hyperthermia for future use as an adjuvant in breast cancer therapy.